Group B Streptococcus vaccine: full value of vaccine assessment. Financial analysis


This report describes the potential financial outcomes that can be expected from successful development of a GBS vaccine that can attain global registration. The report also assesses whether specific additional financing is required to support the clinical development activities. It builds on previous work that described potential scenarios of demand for a GBS vaccine. The report should be read in conjunction with the other workstreams that will contribute to describing the full public health value assessment (FPHVP) – which includes the full health, economic and societal value of a vaccine to a broad range of global stakeholders, including from the perspective of low- and middle-income countries – and aims to explain the full direct (individual) and indirect (population) effects of a GBS vaccine